Industry Pipeline - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Industry Pipeline
Interphex Showcase 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 128-135

Manufacturing capabilities
Lyne Laboratories offers its explosion-proof manufacturing capabilities for high-concentration, flammable pharmaceuticals. Lyne's state-of-the-art facility was designed specifically for formulations high in alcohol content and for solvent-based drug products. Batch sizes range from 1000 to 8000 L. Lyne is registered with the US Food and Drug Administration and licensed by the Drug Enforcement Administration. Lyne Laboratories, Brockton, MA tel. 800.525.0450

Contract Services
Chemic Laboratories is a contract facility that follows good manufacturing and laboratory practices. The company offers extractables-leachables analysis, methods development and validations, bioanalytical services, organic synthesis and formulation development, and stability testing. The independent Chemic Consulting Consortium advises clients throughout their product-development cycles. Chemic Laboratories, Canton, MA tel. 781.821.5600

Contract services
Mikart has provided contract development, manufacturing, and packaging services to the pharmaceutical industry since 1975. The company's capabilities include formulation development; analytical services; solid- and liquid-dose manufacturing; packaging in bottles, blisters, and multilaminate pouches; project management; and regulatory services. Mikart, Atlanta, GA tel. 888.4MIKART

Drug-delivery solutions
For more than 50 years, companies have looked to 3M Drug Delivery Systems for solutions to help their products meet the market's needs. 3M offers inhalation and transdermal drug-delivery systems and components, including dry-powder inhaler and microneedle technologies, plus state-of-the-art contract manufacturing services to help ensure technical success. 3M Drug Delivery Systems, St. Paul, MN tel. 800.643.8086


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here